Author

Daniela Pugliese 1

1 Complesso Integrato Columbus, Catholic University

ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS.

Luisa Guidi, Manuela Marzo, Carla Felice, Daniela Pugliese, Gianluca Andrisani, Giammarco Mocci, Olga Maria Nardone, Gian Lodovico Rapaccini, Alfredo Papa, Alessandro Armuzzi, Gian Lodovico Rapaccini

LONG-TERM OUTCOMES OF ULCERATIVE COLITIS PATIENTS ON MONOTHERAPY MAINTENANCE TREATMENT WITH THIOPURINES: PRELIMINARY DATA

Daniela Pugliese, Pietro Manuel Ferraro, Annalisa Aratari, Giovanna Margagnoni, Rita Monterubbianesi, Carla Felice, Alfredo Papa, Luisa Guidi, Anna Kohn, Claudio Papi, Alessandro Armuzzi

REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD)

Daniela Pugliese, Angela Variola, ANTONINO CARLO Privitera, Mariangela Allocca, Fabrizio Bossa, Maria Cappello, Greta Lorenzon, Silvia Mazzuoli, Mariabeatrice Principi, Renato Sablich, Antonio Ferronato, Stefano Festa, Luisa Moser, Gherardo Tapete, Giorgia Bodini, Maria Di Girolamo, Laurino Grossi, Filippo Mocciaro, Chiar

REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD)

Daniela Pugliese

Early Vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Elisa Gremese, Barbara Tolusso, Clara Di Mario, Alfredo Papa, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

DEEP REMISSION IMPROVES CLINICAL OUTCOMES AFTER INFLIXIMAB DISCONTINUATION IN INFLAMMATORY BOWEL DISEASES

Carla Felice, Daniela Pugliese, Manuela Marzo, Gianluca Andrisani, Olga Maria Nardone, Alfredo Papa, Italo De Vitis, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi

VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Barbara Tolusso, Carla Felice, Alfredo Papa, Italo De Vitis, Elisa Gremese, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Daniela Pugliese

Are we choosing wisely in inflammatory bowel disease care? The IG-IBD choosing wisely campaign

Marco Vincenzo Lenti, Alessandro Armuzzi, Fabiana Castiglione, Massimo Claudio Fantini, Gionata Fiorino, Ambrogio Orlando, Daniela Pugliese, Fernando Rizzello, Maurizio Vecchi, Antonio Di Sabatino

COMBINATION THERAPY PREDICTS LONG-TERM MUCOSAL HEALING IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH ANTI TNF-?

Daniela Pugliese, Pietro Manuel Ferraro, Carla Felice, Gian Lodovico Rapaccini, Alfredo Papa, Luisa Guidi, Alessandro Armuzzi

Item 1 - 10 / 16
1
2